Spanish RNAi drugs shop Sylentis has completed non-human primate studies of a topical siRNA-based treatment for glaucoma and aims to begin testing the drug in humans before the end of the year, RNAi News has learned.

The company will perform initial clinical testing on its own in Spain, though it expects to later test the drug in other countries, including the US, Natalia Wright, Sylentis' head of intellectual property, told RNAi News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.